Bone Loss

Also known as: Osteopenia / Osteopaenia

DrugDrug NameDrug Description
DB06643DenosumabDenosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.
DrugDrug NamePhaseStatusCount
DB06643Denosumab0Completed1
DB06643Denosumab0Recruiting1
DB09153Sodium chloride0Completed1
DB06285Teriparatide1Completed1
DB00878Chlorhexidine1 / 2Not Yet Recruiting1
DB00630Alendronic acid2Completed1
DB00136Calcitriol2Active Not Recruiting1
DB00169Cholecalciferol2Active Not Recruiting1
DB06202Lasofoxifene2Completed1
DB06285Teriparatide2Completed2
DB00399Zoledronic acid2Active Not Recruiting1
DB00399Zoledronic acid2Completed2
DB00399Zoledronic acid2Terminated1
DB00783Estradiol3Withdrawn1
DB01006Letrozole3Completed1
DB00396Progesterone3Withdrawn1
DB00399Zoledronic acid3Completed1
DB01373Calcium4Completed1
DB00153Ergocalciferol4Completed1
DB00282Pamidronic acid4Completed1
DB00884Risedronic acid4Completed3
DB00884Risedronic acid4Recruiting1
DB09299Tenofovir alafenamide4Not Yet Recruiting1
DB06285Teriparatide4Completed1
DB11094Vitamin D4Completed1
DB00399Zoledronic acidNot AvailableCompleted1
DB00399Zoledronic acidNot AvailableRecruiting1